PAHC Earnings Date: Nov 4, 2026 (Estimated) — Phibro Animal Health Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is PAHC's next earnings date?
Phibro Animal Health Corporation (PAHC) is expected to report Q1 2027 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.78 on revenue of $382.4M.
How did PAHC do in its last earnings report?
In its most recent report on Aug 26, 2026 (Q4 2026), Phibro Animal Health Corporation posted EPS of $0.85 versus the $0.71 estimate, a beat of 18.1%. Revenue was $396.7M against a $381.2M estimate. The stock's 1-day post-earnings move was +0.7%.
How much does PAHC stock move after earnings?
PAHC beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.8% (up or down) in the day after earnings.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | Q4 2026 | 0.71 | 0.85 | +18.06% | $396.7M | ✅ Beat | +0.72% | +10.95% | -4.25% |
| 2026-05-06 | Q3 2026 | 0.71 | 0.76 | +7.04% | $383.5M | ✅ Beat | -26.23% | -39.73% | -44.33% |
| 2026-02-04 | Q2 2026 | 0.68 | 0.87 | +27.94% | $373.9M | ✅ Beat | +21.94% | +25.66% | +17.14% |
| 2025-11-05 | Q1 2026 | 0.60 | 0.73 | +21.67% | $363.9M | ✅ Beat | +4.60% | +10.14% | -4.58% |
| 2025-08-27 | Q4 2025 | 0.52 | 0.57 | +9.62% | $378.7M | ✅ Beat | +19.43% | +21.73% | +20.91% |
| 2024-08-28 | Q4 2024 | 0.33 | 0.41 | +24.24% | $273.2M | ✅ Beat | +3.19% | -6.13% | +6.68% |
| 2024-05-08 | Q3 2024 | 0.29 | 0.31 | +6.90% | $263.2M | ✅ Beat | +2.98% | +6.20% | +0.55% |
| 2024-02-07 | Q2 2024 | 0.28 | 0.33 | +17.86% | $249.9M | ✅ Beat | +7.41% | +12.06% | +21.94% |
Showing last 8 quarters.